Dr. Kennecke on Available Treatments for GEP-NETs

Publication
Video
Supplements and Featured PublicationsTherapeutic Updates in Neuroendocrine Tumors
Volume 1
Issue 1

Hagen F. Kennecke, MD, MHA, FRCPC, discusses the treatments available for patients with advanced gastroenteropancreatic neuroendocrine tumors.

Hagen F. Kennecke, MD, MHA, FRCPC, a medical oncologist at Virginia Mason Medical Center, discusses the treatments available for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

When patients have advanced disease, they should always consider surgery first and then get staged with Gallium-68 dotatate (Netspot) PET/CT scans, explains Kennecke. If surgery is not possible, patients receive liver-directed therapy followed by targeted treatment, such as Lutetium-177-PSMA-617 plus chemotherapy or targeted therapy with everolimus (Afinitor), says Kennecke.

Sequencing, according to Kennecke, is less important compared with how urgently patients need therapy and how they react to treatment. If patients require debulking surgery, then surgery, liver-directed therapy, or chemotherapy will be most effective. When a patient has more indolent disease that is positive for receptors, they may be eligible for targeted and radiopeptide therapies, concludes Kennecke.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "